DYNAMICS_Study
What was tested
Treatment tested
- Ozanimod
Sphingosine 1-phosphate receptor 5 modulator
What it measured
Main measures
The primary endpoints of this study are to assess, in RRMS patients treated with ozanimod, the changes from baseline over 2 years of:
Other measures (1)
4. Changes from baseline in cognitive profile (Brief Repeatable Battery of Neuropsychological Tests), in fatigue (Modified Fatigue Impact Scale [MFIS]), in depression (Montgomery and Asberg Depression Rating Scale [MADRS]), and in quality of life ( MSQOL-54);; 1. 2-year changes from baseline in magnetization transfer ratio values ¿¿in white matter lesions, gadolinium-enhancing lesions, apparently
Disability progressionRelapsesMRI lesionsMyelin repairThinking and memoryFatigueMood and sleepQuality of life (reported by participants)
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Sept 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error